BACKGROUND AND MISSION
Sandoz and Ciba-Geigy merged its chemical and life science companies in 1996 to create Novartis. Novartis is now a principle provider of medical products and is present in over 140 countries while maintaining a strong presence in its home country of Switzerland. Novartis is engaged in research and development of new medicines as well as the manufacturing of a number of medications. Novartis has been actively engaged in public health in the developing world. The Novartis Foundation is a philanthropic organization aiming to have a sustainable impact on the health of low-income communities. Working together with governments, universities, NGOs, international organizations and private sector companies, it tackles global health challenges through a mix of programmatic work, health outcomes research, and their translation into policy.

AREAS OF INTEREST
- Leprosy elimination
- Heart health in low income countries
- Healthcare and digital technology
- Malaria
- Training of health professionals

HEALTH-RELATED ACTIVITIES
Novartis Foundation has renewed its commitment to achieve zero leprosy and has launched a strategy that includes early diagnosis and prompt treatment, screening and post-exposure prophylaxis, development of new diagnostics tools and an improved surveillance system. In its fight against NCDs, it is working in communities in low-income countries to improve the awareness, screening and management of hypertension and to promote healthy school. It promotes projects in the area of digital technology and health to raise disease awareness and improve screening, diagnosis and monitoring of diseases. With its programs, Novartis Foundation has reached 7 million people in 14 countries.

GOVERNANCE AND STAFF
The Novartis Foundation is run by a team of 16 members, led by Ann Aerts, who is the Head of the Foundation. The team is monitored by a 6-member board. Chairman of the Board is Joerg Reinhardt.
FUNDING SOURCES AND BUDGET
Novartis Foundation is by Novartis as a part of the corporate responsibility portfolio. The budget for 2017 was CHF 15 million.

PUBLICATIONS
For news releases, see: https://www.novartisfoundation.org/news/news-archive

Last update: 21.08.2019